NYSE - Nasdaq Real Time Price USD

Nuvation Bio Inc. (NUVB)

Compare

1.9900

+0.2400

+(13.71%)

At close: April 11 at 4:00:02 PM EDT

1.9900

0.00

(0.00%)

After hours: April 11 at 7:50:53 PM EDT

Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Insider Monkey 3 days ago

NUVB
+13.71%
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

NEW YORK, April 02, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV.

Business Wire 10 days ago

NUVB
+13.71%
NUVB-WS
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

NEW YORK, March 25, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois.

Business Wire 17 days ago

NUVB
+13.71%
NUVB-WS
Insider Stock Buying Reaches US$720.1k On Nuvation Bio

In the last year, multiple insiders have substantially increased their holdings of Nuvation Bio Inc. ( NYSE:NUVB...

Simply Wall St. 18 days ago

NUVB
+13.71%
NUVB-WS
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

NEW YORK, March 25, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France.

Business Wire 18 days ago

NUVB
+13.71%
NUVB-WS
Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts?

We recently published a list of 10 Most Oversold Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other most oversold penny stocks to buy according to analysts. Small Cap Stocks Outlook 2025 In February 2025, Wellington Management published […]

Insider Monkey 25 days ago

NUVB
+13.71%
^GSPC
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts

We recently compiled a list of the 12 Best NYSE Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against the other NYSE penny stocks. President Trump’s tariffs on Canada and Mexico went live on March 4, 2025, after a one-month […]

Insider Monkey last month

NUVB
+13.71%
^NYA
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

NEW YORK, March 06, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

Business Wire last month

NUVB
+13.71%
NUVB-WS
Nuvation Bio secures $250m for taletrectinib commercialisation

The agreement includes $150m royalty interest financing and a senior term loan of $100m.

Pharmaceutical Technology last month

NUVB
+13.71%
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

NEW YORK, March 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These financings strengthen Nuvation Bio’s balance sheet to fully fund commercialization of taletrectinib in the U.S., if approved,

Business Wire last month

NUVB
+13.71%
NUVB-WS
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, February 24, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA.

Business Wire last month

NUVB
+13.71%
NUVB-WS
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK, February 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available.

Business Wire 2 months ago

NUVB
+13.71%
NUVB-WS
With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest

Key Insights Given the large stake in the stock by institutions, Nuvation Bio's stock price might be vulnerable to...

Simply Wall St. 2 months ago

NUVB
+13.71%
NUVB-WS
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, January 06, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Francisco, California.

Business Wire 3 months ago

NUVB
+13.71%
NUVB-WS
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK, January 06, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that China’s National Medical Products Administration (NMPA) has approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who either have or have not been previously treated with ROS1 tyrosine kinase inhibitors (TKI). As part of an exclusi

Business Wire 3 months ago

NUVB
+13.71%
NUVB-WS
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now?

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […]

Insider Monkey 3 months ago

NUVB
+13.71%
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK, December 23, 2024--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company’s NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23,

Business Wire 3 months ago

NUVB
+13.71%
NUVB-WS
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), f

PR Newswire 3 months ago

IVBIY

IVBXF

NUVB
+13.71%
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

NEW YORK, November 26, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 9:10 a.m. ET.

Business Wire 4 months ago

NUVB
+13.71%
NUVB-WS
Nuvation Bio to Present at the Jefferies London Healthcare Conference

NEW YORK, November 12, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Jefferies London Healthcare Conference in London, U.K., on Tuesday, November 19, 2024, at 3:30 a.m. ET/8:30 a.m. GMT.

Business Wire 4 months ago

NUVB
+13.71%
NUVB-WS

Performance Overview

Return	NUVB	S&P 500 (^GSPC)
YTD	-25.19%	-8.81%
1-Year	-36.83%	+3.16%
3-Year	-62.87%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nuvation Bio Inc. (NUVB)

Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Insider Stock Buying Reaches US$720.1k On Nuvation Bio

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts?

Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nuvation Bio secures $250m for taletrectinib commercialisation

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now?

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Performance Overview